✦ LIBER ✦

Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor

✍ Scribed by Michael Hejna; Gabriela V. Kornek; Markus Raderer; Herbert Ulrich-Pur; Wolfgang C. C. Fiebiger; Leo Marosi; Bruno Schneeweiss; Rosemarie Greul; Werner Scheithauer

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 78 KB
Volume: 89
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20000801)89:3<516::aid-cncr6>3.0.co;2-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-line treatment of advanced nonsmal

First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine

✍ Charalambos Kourousis; Nicos Androulakis; Stelios Kakolyris; John Souglakos; Geo 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

BACKGROUND. Docetaxel and vinorelbine are active agents in the treatment of nonsmall cell lung carcinoma (NSCLC). The efficacy and toxicity of this combination was evaluated in a Phase II study in patients with advanced NSCLC. ## METHODS. Forty-six chemotherapy-naive patients (44 men and 2 women

A phase II study of gemcitabine plus ora

A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma

✍ Tony S. K. Mok; Benny Zee; Anthony T. C. Chan; Winnie Yeo; Wei Tse Yang; Anthony 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

Phase I trial of docetaxel and vinorelbi

Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma

✍ Vincent A. Miller; Kenneth K. Ng; Lee M. Krug; Wendy Perez; Barbara Pizzo; Rober 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

## Background: With preclinical evidence of synergy, this dose-finding trial examining the combination of docetaxel and vinorelbine given with prophylactic filgrastim for the treatment of patients with nonsmall cell lung carcinoma was undertaken. ## Methods: Twenty-seven patients with advanced no

Gemcitabine and docetaxel as second-line

Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens

✍ Christos Kosmas; Nicolas Tsavaris; Maria Vadiaka; Niki Stavroyianni; Angelos Kou 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 1 views

A phase I clinical and pharmacologic stu

A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma

✍ Hiroaki Okamoto; Akira Nagatomo; Hideo Kunitoh; Hiroshi Kunikane; Koshiro Watana 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 1 views

BACKGROUND. This Phase I study was designed to determine the toxicity and efficacy of a carboplatin and irinotecan (CPT-11) regimen with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support for patients with advanced nonsmall cell lung carcinoma. ## METHODS. Treatment consist

High dose tamoxifen plus cisplatin and e

High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma

✍ Chih-Hsin Yang; Ann-Lii Cheng; Kun-Huei Yeh; Chong-Jen Yu; Jing-Fang Lin; Pan-Ch 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## BACKGROUND. Tamoxifen sensitizes cancer cells to chemotherapeutic agents. High dose tamoxifen has been tested in the treatment of patients with melanoma and other cancers. The authors conducted a Phase II study of high dose tamoxifen plus cisplatin and etoposide for patients with advanced, inop